Pristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Virginiamycin M1. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Virginiamycin M1. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Virginiamycin M1. |
| Dicoumarol | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Virginiamycin M1 is combined with (S)-Warfarin. |
| Lactulose | The therapeutic efficacy of Lactulose can be decreased when used in combination with Virginiamycin M1. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Virginiamycin M1. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Virginiamycin M1. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Quinisocaine. |
| Cisatracurium | Virginiamycin M1 may increase the neuromuscular blocking activities of Cisatracurium. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Virginiamycin M1 is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Virginiamycin M1. |